BTK Inhibitor-Resistant Lymphoma Animal Models

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in Western populations. Targeted therapies, including the use of BTK inhibitors, have significantly improved the care of patients with CLL. However, over time, many patients develop resistance to these drugs. Acquired resistance to the BTK inhibitor ibrutinib is mediated by the C481S mutation, which decreases binding affinity and changes binding from irreversible to reversible.  Unlike C481S, which results in a kinase that retains activity, the L528W mutation in BTK prevents both the binding of covalent inhibitors and the binding of ATP.

To bolster the research of innovative cancer drugs and to emulate real-world clinical scenarios of drug resistance, WuXi Biology has established REC1 lymphoma cell lines and animal models carrying the BTK C481S mutation or L528W mutation.

BTK inhibitor-resistant REC1 lymphoma cell lines and models

Download